RT Journal Article
SR Electronic
T1 Identification of biomarkers, pathways, and therapeutic targets for EGFR–TKI resistance in NSCLC
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202302110
DO 10.26508/lsa.202302110
VO 6
IS 12
A1 Zhu, Leilei
A1 Gao, Shanshan
A1 Zhao, Xianya
A1 Wang, Ying
YR 2023
UL https://www.life-science-alliance.org/content/6/12/e202302110.abstract
AB This study aimed to map the hub genes and potential pathways that might be involved in the molecular pathogenesis of EGFR–TKI resistance in NSCLC. We performed bioinformatics analysis to identify differentially expressed genes, their function, gene interactions, and pathway analysis between EGFR–TKI-sensitive and EGFR–TKI-resistant patient-derived xenotransplantation samples based on Gene Expression Omnibus database. Survival analysis was performed via the GEPIA database (GEO). The relationship between the key gene ITGAM and the therapeutic candidates was retrieved from DGIdb. A total of 1,302 differentially expressed genes were identified based on GEO. The PPI network highlighted 10 potential hub genes. Only ITGAM was linked to poor DSF in NSCLC patients. A total of 10 drugs were predicted to be potential therapeutics for NSCLC with EGFR–TKI resistance. This study indicates the hub genes related to EGFR–TKI resistance in NSCLC through bioinformatics technologies which can improve the understanding of the mechanisms of EGFR–TKI resistance and provide novel insights into therapeutics.